Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2022

May 17, 2022

SELL
$21.19 - $40.01 $2.17 Million - $4.11 Million
-102,600 Reduced 47.35%
114,100 $2.94 Million
Q4 2021

Feb 15, 2022

BUY
$30.97 - $54.03 $4.43 Million - $7.74 Million
143,200 Added 194.83%
216,700 $9.07 Million
Q3 2021

Nov 16, 2021

BUY
$34.9 - $54.54 $554,910 - $867,186
15,900 Added 27.6%
73,500 $3.2 Million
Q2 2021

Aug 16, 2021

SELL
$38.75 - $51.0 $2.03 Million - $2.67 Million
-52,400 Reduced 47.64%
57,600 $2.72 Million
Q1 2021

May 18, 2021

BUY
$26.34 - $83.07 $1.54 Million - $4.87 Million
58,600 Added 114.01%
110,000 $5.64 Million
Q4 2020

Feb 17, 2021

SELL
$25.51 - $43.38 $216,835 - $368,730
-8,500 Reduced 14.19%
51,400 $1.38 Million
Q3 2020

Nov 17, 2020

BUY
$28.28 - $53.6 $1.18 Million - $2.24 Million
41,800 Added 230.94%
59,900 $2.06 Million
Q2 2020

Aug 17, 2020

BUY
$27.89 - $47.86 $504,809 - $866,266
18,100 New
18,100 $742,000

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $944M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.